Janssen persuades Scotland to reimburse Zytiga
This article was originally published in Scrip
Janssen has managed to convince the Scottish Medicines Consortium, Scotland's health technology appraisal body, that the benefits of its anticancer Zytiga (abiraterone) do in fact justify the cost. The consortium has this week accepted the drug for use on the Scottish NHS for patients with metastatic castration resistant prostate cancer.
You may also be interested in...
Industry access to real world data for regulatory and market access purposes in Asia Pacific compares poorly with the US.
Draft guidelines due out for consultation this week in Italy are expected to shed more light on what companies will have to reveal during pricing and reimbursement negotiations.
Germany is for the first time to adopt national guidelines on prescribing biologics and biosimilars in a move towards increasing biosimilar uptake.